Rhelion Life Sciences (STU:4YX0) Institutional Ownership: 0.19% (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhelion Life Sciences Institutional Ownership?

Rhelion Life Sciences STU:4YX0 -71.43% Institutional Ownership is 0.19% as of Sep. 22, 2026. The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rhelion Life Sciences's institutional ownership is 0.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rhelion Life Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rhelion Life Sciences's Float Percentage Of Total Shares Outstanding is 0.00%.

Rhelion Life Sciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Rhelion Life Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhelion Life Sciences Institutional Ownership Chart

Rhelion Life Sciences Historical Data

The historical data trend for Rhelion Life Sciences can be seen below:

2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30
Institutional Ownership 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19

Rhelion Life Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.19% mean?
Rhelion Life Sciences (STU:4YX0) has a Institutional Ownership of 0.19% as of Sep. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' Institutional Ownership too high?
Rhelion Life Sciences' current Institutional Ownership is 0.19%.
How does Rhelion Life Sciences' Institutional Ownership compare to ZTS?
Rhelion Life Sciences' Institutional Ownership of 0.19% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current Institutional Ownership is 0.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Rhelion Life Sciences (STU:4YX0) has a current Institutional Ownership of 0.19%. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 99% below its estimated fair value. The current Institutional Ownership is 0.19%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current Institutional Ownership is 0.19% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhelion Life Sciences Business Description

Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Rhelion Life Sciences Corp is a pharmaceutical research and development company focused on natural psychedelic medicines for psychiatric and neurological conditions. The company is engaged in the discovery and development of drug candidates derived from naturally occurring psychoactive compounds, targeting indications such as depression, anxiety, post-traumatic stress disorder, and other mental health disorders. Its activities center on preclinical and clinical research, formulation development, and regulatory pathways for psychedelic-based therapeutics. As a development-stage company, Rhelion does not yet market approved products and relies on equity financing, grants, and partnership arrangements to fund its research programs. Its primary market is the United States, with potential expansion into other jurisdictions where regulatory frameworks permit psychedelic-assisted therapy research and commercialization. The company operates in the emerging psychedelic medicine sector, competing with other biopharmaceutical firms pursuing synthetic and natural psychedelic compounds.